Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Mab™
HUGO-Light™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Peer-Reviewed Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Stk17bem1flox/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Stk17bem1flox/Cya

Common Name
Stk17b-flox
Product ID
S-CKO-17308
Backgroud
C57BL/6JCya
Strain ID
CKOCMP-98267-Stk17b-B6J-VA
Status
Research and Development
When using this mouse strain in a publication, please cite “Stk17b-flox Mouse (Catalog S-CKO-17308) were purchased from Cyagen.”
cKO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
cKO Models
Basic Information
Strain Name
Stk17b-flox
Strain ID
CKOCMP-98267-Stk17b-B6J-VA
Gene Name
Stk17b
Product ID
S-CKO-17308
Gene Alias
Drak2, 3110009A03Rik
Background
C57BL/6JCya
NCBI ID
98267 (Mouse)
Modification
Conditional knockout
Chromosome
Chr 1 (Mouse)
Phenotype
MGI:2138162
Datasheet
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000027263
NCBI Transcript ID
NM_133810
Target Region
Exon 4
Size of Effective Region
~1.2 kb
Overview of Gene Research
Stk17b, also known as DRAK2, is a serine/threonine protein kinase belonging to the death-associated protein kinase family. It is involved in various biological processes such as setting the threshold for T cell activation, regulating Purkinje cell dendritic development, and is associated with pathways like AKT/GSK-3β/Snail. It has been genetically linked to the development of diverse diseases, making it an important gene for understanding disease mechanisms [4,5,7].

In cancer research, Stk17b has been found to be highly expressed in ovarian cancer, hepatocellular carcinoma, and glioma tissues, promoting tumor cell proliferation, invasion, and migration. For example, in ovarian cancer, silencing Stk17b suppressed cell progression, while overexpression promoted it, with Stk17b increasing cell invasion and migration by promoting the EMT process [1]. In hepatocellular carcinoma, inhibition of Stk17b inhibited tumorigenesis and metastasis, and it was found to promote the EMT process via the AKT/GSK-3β/Snail signal pathway [3]. In glioma, methionine deprivation-induced inhibition of Stk17b suppressed cell proliferation and the EMT process [6]. In skin cutaneous melanoma, Stk17b had lower expression compared to normal tissues, and its low expression was correlated with poor overall survival and disease-specific survival, and it was also related to immune infiltration [2].

In conclusion, Stk17b plays a crucial role in multiple biological processes and disease conditions, especially in cancer progression. Its role in promoting tumorigenesis and metastasis in various cancers, as well as its association with immune-related processes in skin cutaneous melanoma, makes it a potential target for cancer diagnosis, prognosis, and immunotherapy. The findings from these functional studies help in understanding the complex mechanisms underlying these diseases and may lead to the development of novel therapeutic strategies.

References:
1. Jiang, Liping, Zhou, Jinhua, Zhao, Shaojie, Wang, Xuzhen, Chen, Youguo. . STK17B promotes the progression of ovarian cancer. In Annals of translational medicine, 9, 475. doi:10.21037/atm-21-601. https://pubmed.ncbi.nlm.nih.gov/33850872/
2. Shi, Xueying, Zhou, Qi, Huang, Bingqian, Fang, Shifeng, Lin, Jingrong. 2022. Prognostic and immune-related value of STK17B in skin cutaneous melanoma. In PloS one, 17, e0263311. doi:10.1371/journal.pone.0263311. https://pubmed.ncbi.nlm.nih.gov/35171924/
3. Lan, Yaliang, Han, Jihua, Wang, Yan, Subash, Sharma, Liu, Lianxin. 2018. STK17B promotes carcinogenesis and metastasis via AKT/GSK-3β/Snail signaling in hepatocellular carcinoma. In Cell death & disease, 9, 236. doi:10.1038/s41419-018-0262-1. https://pubmed.ncbi.nlm.nih.gov/29445189/
4. Scheuplein, Felix, Renner, Florian, Campbell, John E, Dorsch, Marion, Bischoff, James R. 2024. Evaluation of STK17B as a cancer immunotherapy target utilizing highly potent and selective small molecule inhibitors. In Frontiers in immunology, 15, 1411395. doi:10.3389/fimmu.2024.1411395. https://pubmed.ncbi.nlm.nih.gov/39502695/
5. Wu, Qin-Wei, Kapfhammer, Josef P. 2021. Serine/threonine kinase 17b (STK17B) signalling regulates Purkinje cell dendritic development and is altered in multiple spinocerebellar ataxias. In The European journal of neuroscience, 54, 6673-6684. doi:10.1111/ejn.15465. https://pubmed.ncbi.nlm.nih.gov/34536317/
6. Li, Jiafeng, Liu, Ruijie, Hu, Hong, Wang, Kaikai, Liu, Huailei. 2024. Methionine deprivation inhibits glioma proliferation and EMT via the TP53TG1/miR-96-5p/STK17B ceRNA pathway. In NPJ precision oncology, 8, 270. doi:10.1038/s41698-024-00763-y. https://pubmed.ncbi.nlm.nih.gov/39572759/
7. Liu, Chang, Zhang, Yichi, Zhang, Yuqing, Mao, Feifei, Chai, Zongtao. 2022. Mechanistic Insights into the Mechanism of Inhibitor Selectivity toward the Dark Kinase STK17B against Its High Homology STK17A. In Molecules (Basel, Switzerland), 27, . doi:10.3390/molecules27144655. https://pubmed.ncbi.nlm.nih.gov/35889528/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research